---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-277563"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-06-22T20:21:25+00:00"
generated_at: "2026-06-22T20:22:38.382034+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics annual meeting: all director nominees elected, auditor and say-on-pay approved.

## Summary
- Directors elected: Nancy Miller-Rich (35.9M for, 1.2M withheld), John Milligan (35.8M for, 1.3M withheld), Shawn Tomasello (30.5M for, 6.6M withheld). Broker non-votes ~7.0M.
- Ratification of PwC as auditor: 43.9M for, 55.8K against, 81.9K abstain.
- Advisory say-on-pay approved: 36.1M for, 940K against, 67.4K abstain, 7.0M broker non-votes.

## SEC filing metadata
- accession: 0001193125-26-277563
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-06-22T20:21:25+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/0001193125-26-277563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/fdmt-20260617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-277563
- JSON: https://secwatch.observer/filing/0001193125-26-277563.json
- Plain text: https://secwatch.observer/filing/0001193125-26-277563.txt

## Key facts
- Shareholder Votes
  4D Molecular Therapeutics, Inc. shareholders approved Election of Class III directors at the 2026-06-17 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 1. The Company’s stockholders elected by a plurality of votes cast the Class III director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. NOMINEE FOR WITHHELD BROKER NON-VOTES Nancy Miller-Rich 35,880,028 1,193,202 6,964,792 John F. Milligan, Ph.D. 35,778,121 1,295,109 6,964,792 Shawn Cline Tomasello, MBA 30,508,706 6,564,524 6,964,792
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/0001193125-26-277563-index.htm
- Shareholder Votes
  4D Molecular Therapeutics, Inc. shareholders approved Ratification of selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 2. The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN 43,900,362 55,763 81,897
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/0001193125-26-277563-index.htm
- Shareholder Votes
  4D Molecular Therapeutics, Inc. shareholders approved Advisory, non-binding vote on named executive officers’ compensation at the 2026-06-17 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 3. The Company’s stockholders approved, on an advisory, non-binding basis, the named executive officers’ compensation as disclosed in the Proxy Statement. FOR AGAINST ABSTAIN BROKER NON-VOTES 36,065,437 940,414 67,379 6,964,792
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312526277563/0001193125-26-277563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.